Oruka Therapeutics (NASDAQ:ORKA) Stock: Insider Kristine Ball Sells 18,000 Shares

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Director Kristine Ball sold 18,000 shares of Oruka Therapeutics stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $104.93, for a total value of $1,888,740.00. Following the transaction, the director directly owned 18,000 shares of the company’s stock, valued at approximately $1,888,740. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oruka Therapeutics Stock Up 0.3%

Shares of NASDAQ:ORKA traded up $0.36 on Friday, hitting $105.35. The stock had a trading volume of 679,678 shares, compared to its average volume of 1,033,539. The firm’s 50 day moving average price is $89.68 and its 200-day moving average price is $72.36. Oruka Therapeutics, Inc. has a twelve month low of $25.23 and a twelve month high of $115.51.

Oruka Therapeutics (NASDAQ:ORKA) last announced its earnings results on Monday, November 9th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). Equities research analysts predict that Oruka Therapeutics, Inc. will post -2.52 earnings per share for the current fiscal year.

Institutional Trading of Oruka Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ORKA. Nykredit A S bought a new position in shares of Oruka Therapeutics in the second quarter valued at about $29,000. GAMMA Investing LLC lifted its position in Oruka Therapeutics by 201.6% during the 3rd quarter. GAMMA Investing LLC now owns 374 shares of the company’s stock worth $31,000 after buying an additional 250 shares in the last quarter. Orion Capital Management LLC bought a new stake in Oruka Therapeutics during the 2nd quarter worth about $91,000. Sterling Capital Management LLC grew its holdings in Oruka Therapeutics by 839.0% during the 3rd quarter. Sterling Capital Management LLC now owns 1,662 shares of the company’s stock worth $138,000 after acquiring an additional 1,485 shares during the last quarter. Finally, Royal Bank of Canada grew its holdings in Oruka Therapeutics by 178.5% during the 1st quarter. Royal Bank of Canada now owns 3,172 shares of the company’s stock worth $155,000 after acquiring an additional 2,033 shares during the last quarter. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Key Oruka Therapeutics News

Investors following ORKA have been watching these news items:

• Positive Sentiment: BTIG Research and UBS each assigned Oruka a “Buy” rating, providing a positive analyst view. BTIG Research Buy rating UBS Buy rating
• Negative Sentiment: HC Wainwright cut its estimates for every quarter of 2027 and for full-year 2026 and 2027, while keeping its Buy rating. It now expects losses of $2.69 per share in FY2026 and $3.22 in FY2027, versus prior estimates of $2.54 and $2.82, respectively. The deeper projected losses may dampen sentiment.
• Negative Sentiment: Director Kristine M. Ball sold 18,000 shares—half her position—and SVP Arjun Agarwal sold 10,000 shares, reducing his holdings by 41.29%. Both sales were made under pre-arranged Rule 10b5-1 plans, which may lessen their significance as a signal about near-term prospects. Director Form 4 filing SVP Form 4 filing

Analyst Ratings Changes

Several analysts have weighed in on the stock. Wall Street Zen cut shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. HC Wainwright reiterated a “buy” rating on shares of Oruka Therapeutics in a research note on Tuesday, October 27th. Mizuho set a $120.00 target price on shares of Oruka Therapeutics in a research note on Thursday, September 3rd. Piper Sandler reissued an “overweight” rating on shares of Oruka Therapeutics in a report on Wednesday, October 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Tuesday, October 13th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $141.80.

About Oruka Therapeutics

Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments. The company’s pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.